Inhibitor Therapeutics Reports 2026 Annual Meeting Results, Board Elections

What Happened

• Inhibitor Therapeutics, Inc. (INTI) filed an 8‑K on Sept. 18, 2026 reporting results of its Sept. 15, 2026 Annual Meeting of Stockholders. Six director nominees — Francis E. O’Donnell, Samuel J. Sears, Niraj Vasisht, Michelle Yanez, Michael Jerman and Ronald E. Osman — were elected to one‑year terms expiring at the 2027 annual meeting.
• Stockholders also ratified Cherry Bekaert LLP as the company’s independent registered public accounting firm for fiscal 2026, approved the 2025 Share Incentive Plan, approved the non‑binding advisory vote on executive compensation (“say‑on‑pay”), and expressed a preference on the frequency of future say‑on‑pay votes.

Key Details

• Director election vote totals:
  • Francis E. O’Donnell, Samuel J. Sears, Niraj Vasisht, Ronald E. Osman: 96,676,056 For; 2,783,870 Withheld; 12,986,028 Broker Non‑Votes.
  • Michelle Yanez and Michael Jerman: 98,342,951 For; 1,116,975 Withheld; 12,986,028 Broker Non‑Votes.
• Auditor ratification (Cherry Bekaert LLP): 110,776,019 For; 1,668,434 Against; 1,501 Abstentions.
• 2025 Share Incentive Plan: 96,249,721 For; 3,208,603 Against; 1,602 Abstentions; 12,986,028 Broker Non‑Votes.
• Say‑on‑pay (advisory): 96,854,767 For; 2,605,058 Against; 101 Abstentions; 12,986,028 Broker Non‑Votes.
• Frequency of advisory votes on executive compensation: stockholders indicated a preference for every 3 years (76,086,572 votes), versus 1 year (22,443,829) and 2 years (10,501); 919,024 Abstain; 12,986,028 Broker Non‑Votes.

Why It Matters

• Board continuity: Re‑election of six directors keeps current governance in place through the 2027 annual meeting, which matters for strategic direction and oversight.
• Financial oversight and reporting: Ratification of Cherry Bekaert LLP confirms the firm that will audit fiscal 2026 financials.
• Compensation and dilution: Approval of the 2025 Share Incentive Plan enables the company to grant equity awards (potential dilution over time); say‑on‑pay approval indicates stockholder support for current executive compensation practices.
• Governance cadence: The advisory preference for triennial say‑on‑pay votes (3 years) may reduce the frequency of formal advisory votes on executive pay, though such votes remain non‑binding.